Neurocrine Biosciences, Inc. (BVMF:N1BI34)

Market Cap	73.48B -16.9%
Revenue (ttm)	14.30B +19.6%
Net Income	2.28B +10.9%
EPS	22.34 +12.4%
Shares Out	n/a
PE Ratio	32.22
Forward PE	14.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35
Average Volume	376
Open	34.08
Previous Close	n/a
Day's Range	34.08 - 34.08
52-Week Range	25.64 - 44.18
Beta	0.31
RSI	35.72
Earnings Date	Feb 11, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,800
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: N1BI34

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD